RT Journal Article
SR Electronic
T1 Mapping the Regional Distribution of Molecular Tumor Board Patients and Identifying White Spots in our Catchment Area – a Joint Approach of the CCC WERA Alliance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.15.22275106
DO 10.1101/2022.05.15.22275106
A1 Florian Lüke
A1 Florian Haller
A1 Kirsten Utpatel
A1 Markus Krebs
A1 Norbert Meidenbauer
A1 Alexander Scheiter
A1 Silvia Spörl
A1 Daniel Heudobler
A1 Felix Keil
A1 Christoph Schubart
A1 Lars Tögel
A1 Sabine Einhell
A1 Wolfgang Dietmaier
A1 Ralf Huss
A1 Sebastian Dintner
A1 Sebastian Sommer
A1 Frank Jordan
A1 Maria-Elisabeth Goebeler
A1 Michaela Metz
A1 Diana Haake
A1 Mithun Scheytt
A1 Elena Gerhard-Hartmann
A1 Katja Maurus
A1 Stephanie Brändlein
A1 Andreas Rosenwald
A1 Arndt Hartmann
A1 Bruno Märkl
A1 Hermann Einsele
A1 Andreas Mackensen
A1 Wolfgang Herr
A1 Volker Kunzmann
A1 Ralf Bargou
A1 Matthias W. Beckmann
A1 Tobias Pukrop
A1 Martin Trepel
A1 Matthias Evert
A1 Rainer Claus
A1 Alexander Kerscher
YR 2022
UL http://medrxiv.org/content/early/2022/05/16/2022.05.15.22275106.abstract
AB Background Molecular Tumor Boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional impact and the outreach component of MTBs.Methods We analyzed MTB patient data from four neighboring Bavarian tertiary care oncology centers in Würzburg, Erlangen, Regensburg, and Augsburg, together constituting the WERA Alliance. Absolute patient numbers and regional distribution across the WERA-wide catchment area were weighted with local population densities.Results Highest MTB patient numbers were found close to the four cancer centers. However, peaks in absolute patient numbers were also detected in more distant and rural areas. Moreover, weighting absolute numbers with local population density allowed us to identify regions within our catchment area relatively underrepresented in WERA MTBs.Conclusion Investigating patient data from four neighboring cancer centers, we comprehensively assessed the regional impact of our MTBs. The results confirmed the success of existing collaborative structures with our regional partners. Additionally, our results help identifying potential white spots in precision oncology and establishing a joint WERA-wide outreach strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the University of Regensburg gave ethical approval for this work (Molecular Tumor Board Registry Study, protocol code 20-1682-101).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors